Atlal Abusanad, Executive Director at King AbdulAziz University, shared on LinkedIn:
“Amid the ongoing debate surrounding SERENA-6 and the differing views on early ESR1-guided endocrine switching, I share a balanced perspective that moves beyond a binary ‘for or against’ position. This article proposes a risk-adapted approach, integrating clinical, molecular, and temporal factors to guide when ESR1-directed intervention is most appropriate, rather than relying on molecular detection alone.”
Title: ESR1-Guided Endocrine Switching in HR-Positive Metastatic Breast Cancer: From Detection to Risk-Adapted Decision in SERENA-6
Authors: Atlal Abusanad
Read the full article.
This also can be interesting:
